Johnson & Johnson (NYSE: JNJ) has agreed to acquire Firefly Bio, Inc. for USD 1 billion in cash, adding the company's proprietary Firelink degrader antibody conjugate (DAC) platform to its oncology pipeline. The US-based acquirer indicated the deal is intended to expand its capabilities in targeting pan-KRAS-driven solid tumors, where existing therapeutic options remain limited.
The agreement is structured as an outright cash acquisition of the entire company, with no disclosed milestone payments, royalties, or contingent value rights. Closing is subject to applicable regulatory approvals and customary conditions, expected later in 2026. J&J acquires all Firefly Bio assets, intellectual property, and pipeline programs on a global basis.
Firefly Bio's Firelink platform is designed to deliver highly selective protein degraders directly to tumor cells via antibody conjugation, seeking to combine the tumor-targeting specificity of antibody engineering with the intracellular mechanism of targeted protein degradation. The approach is intended to address a core limitation of small-molecule KRAS inhibitors — selectivity against tumor cells versus healthy tissue — by using the antibody component to restrict degrader payload delivery to antigen-expressing cancer cells. The platform's lead focus is KRAS-mutant solid tumors, a target historically resistant to direct pharmacological intervention. Development stage assets are described as preclinical candidates.
The KRAS space has attracted significant large-pharma capital at early development stages. AbbVie recently secured an exclusive option to acquire Kestrel Therapeutics for up to USD 1.45 billion for KST-6051, a pan-KRAS inhibitor targeting KRAS-mutant solid tumors — a structurally different approach to the same oncogenic driver. J&J's USD 1 billion all-cash structure, by contrast, reflects a preference for outright platform ownership over option-based contingency arrangements, consistent with its prior acquisition of Halda Therapeutics for USD 3.05 billion to access a targeted protein degrader platform for oncology.